Adrenocortical Carcinoma Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The adrenocortical carcinoma treatment market size is expected to increase from USD 642.60 million in 2025 to USD 679.04 million in 2026 and reach USD 894.65 million by 2031, growing at a CAGR of 5.67% over 2026-2031. This report is Segmented by Treatment Type (Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, and Immunotherapy), by Disease Stage (Localized Stage, Locally Advanced Stage, and Metastatic Stage), by End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and More), and by Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Adrenocortical Carcinoma Treatment Market Trends and Insights

Rising Adoption of Precision Oncology for Rare Endocrine Cancers

The Adrenocortical carcinoma treatment market is moving toward molecular selection rather than uniform treatment use. IGF2 overexpression is present in nearly 90% of tumors, and Wnt and β-catenin pathway disruption appears in up to 54% of cases, which gives researchers repeatable targets across a disease that was once treated in a far more uniform way. A 2025 study in npj Precision Oncology showed that more than 70% of high-SIS patients were predicted responders to immune checkpoint blockade, while more than 65% of low-SIS patients were flagged as biologically resistant. That kind of split matters because it can reduce avoidable trial failure in a disease with very limited patient numbers. The result is that the Adrenocortical carcinoma treatment market is starting to favor developers that can match therapy design with companion testing and more precise enrollment.

Expansion of Orphan Drug Development and Regulatory Incentives

The Adrenocortical carcinoma treatment market continues to benefit from orphan-focused policy support because trial economics in this disease are difficult without exclusivity and development incentives. In both the United States and Europe, orphan frameworks reduce commercial risk for sponsors that would otherwise struggle to justify Phase 2 work in an indication with very low annual incidence. That support is visible in public registries, where small and mid-sized programs continue to move forward in rare endocrine oncology despite limited enrollment pools. The same pattern appears in investigator-led work, where advanced ACC studies continue in national multicenter settings that would be difficult to sustain without regulatory and procedural backing. This has widened the set of companies willing to enter the Adrenocortical carcinoma treatment market even before any new product reaches approval.

Very Small Patient Pool Limiting Trial Scale and Commercial Uptake

The Adrenocortical carcinoma treatment market remains constrained by incidence that is usually cited at only 1 to 2 cases per million people each year. Small patient numbers do not just slow trials, they also limit the commercial depth available after launch. That problem was clearly visible when the MD Anderson pembrolizumab plus mitotane study ended after enrolling only 3 patients, even though the clinical rationale for the combination was strong. Limited scale also means that developers must recover research costs across a narrow treated population, which can make pricing and reimbursement more difficult in systems without clear rare-disease funding pathways. For that reason, the Adrenocortical carcinoma treatment market still depends heavily on a small number of tertiary centers that can identify, route, and treat patients consistently.

Other drivers and restraints analyzed in the detailed report include:

• Higher Use of Multimodal Therapy in Advanced and Metastatic Disease
• Genomic Profiling Revealing Actionable Subsets for Trial Enrollment
• Severe Toxicity and Monitoring Burden of Current Systemic Therapies

Segment Analysis

In the Adrenocortical carcinoma treatment market, surgery led treatment revenue with a 41.30% share in 2025 because it remains the only curative option for localized disease. Open adrenalectomy still dominates practice, while laparoscopic surgery is limited to selected tumors under 6 cm without local invasion, which keeps procedure volume concentrated in high-volume centers. Chemotherapy remained the next important treatment pillar through EDP-M, but the mitotane effect on etoposide exposure continues to complicate dose planning and treatment consistency. Radiation therapy held a smaller base, yet recent evidence has strengthened its position as an adjunct for locoregional control and selected metastatic settings.

In the Adrenocortical carcinoma treatment market, targeted therapy is set to grow at the fastest 7.23% CAGR through 2031 as new combinations show more activity than older single-agent approaches. The CaboACC Phase 2 dataset reported a 78% disease control rate, an 11% objective response rate, and median progression-free survival of 6 months for cabozantinib in advanced ACC. The camrelizumab plus apatinib combination also stood out with an objective response rate near 50% and median progression-free survival of 12.6 months, which supports VEGFR and PD-1 dual targeting over checkpoint monotherapy. Within the adrenocortical carcinoma treatment industry, this suggests that future value creation is more likely to come from combination-led targeted regimens than from incremental use of older cytotoxic backbones.

Complete Report Scope:

• By Treatment Type
  • Surgery
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Immunotherapy
• By Disease Stage
  • Localized Stage
  • Locally Advanced Stage
  • Metastatic Stage
• By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Research and Academic Institutions
  • Home Healthcare Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In the Adrenocortical carcinoma treatment market, North America held the largest regional share at 43.38% in 2025 because the region combines strong referral networks, rare-disease reimbursement support, and a high concentration of specialized cancer centers. The United States also remains central to evidence generation, with the National Cancer Institute launching the Phase 2 cabozantinib plus cemiplimab trial in February 2026 with a planned 48-patient cohort that includes adolescents and adults. Canada supports treatment continuity through updated product guidance, and the December 2024 Lysodren monograph revision aligned national labeling with more recent safety and interaction standards. In revenue terms, North America accounted for 43.38% of the Adrenocortical carcinoma treatment market size in 2025 because clinical access and reimbursement are more established here than in most other regions.

In the Adrenocortical carcinoma treatment market, Europe remained the second-largest region, led by Germany, France, the United Kingdom, and Italy. The region still carries much of the foundational treatment evidence because the major European groups helped define standards used in surgery, adjuvant treatment, and systemic care. Lysodren maintained full EMA marketing authorization for advanced, unresectable, metastatic, or relapsed ACC, and the most recent product information update in April 2025 preserved its position as the default systemic option across Europe. Europe also continues to host trial activity and multidisciplinary treatment planning that keep commercial activity concentrated in academic referral hospitals.

In the Adrenocortical carcinoma treatment market, Asia-Pacific is projected to record the fastest regional CAGR at 7.46% through 2031 as cancer infrastructure expands and incidental detection rises with broader imaging use. China has become more visible in clinical evidence after the camrelizumab plus apatinib Phase 2 study reported stronger activity than most single-agent immunotherapy data in previously treated ACC. South Korea is also contributing through the ACCOMPLISH trial of pembrolizumab plus lenvatinib, which remains active in post-platinum disease and is expected to complete primary evaluation in 2027. Japan and India support the regional outlook through broader oncology capacity rather than through a large volume of branded ACC-specific commercial assets.

List of Companies Covered in this Report:

• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Corcept Therapeutics Incorporated
• Cytovation AS
• Daiichi Sankyo
• EnGeneIC Ltd.
• Enterome
• EUSA Pharma
• Exelixis, Inc.
• HRA Pharma
• Ipsen
• Merck
• Millendo Therapeutics, Inc.
• Mundipharma International Limited
• Novartis
• Orphagen Pharmaceuticals, Inc.
• Pfizer
• Sanofi
• Takeda Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support